2014 Brand of the Year - Pharmaceutical Executive

ADVERTISEMENT

2014 Brand of the Year


Pharmaceutical Executive


The price of prevention

Copaxone is a disease-modifying therapy, but it doesn't stop the progression of MS. Patients and physicians, as evidenced by the level of utilization, are confident the drug does slow exacerbations of the disease, despite a Cochrane review that found "no beneficial effects on disease progression," and only a "slight beneficial effect in the reduction of risk of relapses in relapse-remitting MS patients." Slight is better than nothing, and patients wouldn't keep injecting themselves everyday if they believed otherwise.

A neurologist and professor at one of America's top academic medical institutions—who asked to remain nameless for this article—said Copaxone's "importance lay in showing that an approach of this type can work, albeit modestly...that said, we have no definite idea of its mechanism of action."

To date, there haven't been any generic versions of disease-modifying MS drugs, which means that when a new product is approved, and priced, all the other products increase up to the new price level. "Pricing of MS drugs is a national scandal," said the professor, responding to a question about potential generic versions of Copaxone. "Anything that makes them more affordable is welcome."

Derkacz says Copaxone "has never been a price leader...and its pricing is largely reflective of investments made to research as the market-leading MS therapy." Derkacz also emphasizes the value and services built in to the cost; those nurses working for Shared Solutions might be free for patients to call, but they don't work for free. If a generic version does launch, how do payers put a value on injection frequency, particularly for patients who've developed injection site reactions?

It's not just MS, of course. Even products that are effectively curative, like Gilead's Sovaldi, for hepatitis C virus, are being challenged on price. For drugs targeting chronic conditions, where patients must take them indefinitely, often for the rest of their lives, pricing pressures will continue and are likely to intensify. Within the current system, the best cost solution is both the simplest and the most difficult: discover a cure, pay a premium, then develop a generic version. MS patients, their families, payers and even some taxpayers are willing to pay a little more in the short term for an assurance that the disease never comes back in the long run.








Ben Comer is Pharm Exec's Senior Editor. He can be reached at
.


ADVERTISEMENT

blog comments powered by Disqus
UPCOMING CONFERENCES

Serialization Summit
San Diego, CA
Feb. 27-28, 2014



Advances in Aseptic Processing
San Diego, CA
Mar. 10-12, 2014



ClinTech 2014
Cambridge, MA
Mar. 11-13 2014


Investigator-Initiated and
Sponsored Research (IISR)

Philadelphia, PA
Mar. 19-20 2014

See All Conferences >>

Source: Pharmaceutical Executive,
Click here